This is the practical walkthrough. If you have a 23andMe account and you want to know what a drug response report looks like when run against your data, here's what actually shows up: which medications are flagged, what the recommendations say, how to use them with your doctor.
A pharmacogenetic report does not tell you to start, stop, or change a medication. It provides information for you and your clinician to use together. Medication decisions should always involve your prescribing provider.
When your doctor writes a prescription, they're making an educated guess that the standard dose will work for you. For most medications and most patients, it does. For a meaningful minority, it doesn't. A drug response report tells you in advance which medications are worth paying closer attention to, based on your genotype. You don't need a new test for this if you have 23andMe data; the relevant genetic markers are already in the raw data file you can download.
The report groups medications into categories based on your metabolizer phenotype for each relevant gene. A typical output for someone who turns out to be a CYP2C19 intermediate metabolizer: sertraline flagged with a dose-reduction recommendation, escitalopram flagged with a similar note, citalopram flagged with a maximum-dose cap, omeprazole flagged with dose-frequency guidance, clopidogrel flagged with an alternative-therapy note. Each flag links to the underlying CPIC or FDA guideline so you can see exactly what the clinical basis is.
Most prescribing clinicians will accept a pharmacogenetic report as useful information, especially for medications where CPIC has published dosing guidelines. Practical approach: share the report before your next prescription decision (not after a medication has already failed you), highlight the specific recommendations relevant to what you're discussing, and let your clinician decide how to factor the information in. The report doesn't tell you to change any medication on its own; it gives your clinician better information to make the call.
The report covers 103 medications across psychiatric, cardiovascular, pain, chemotherapy, transplant, and gastrointestinal drug classes. Many of these you won't be taking. That's the point. Your metabolizer phenotype is a lifelong fact, and the report is a reference document you'll pull out years from now when a doctor prescribes something new. A patient who discovers they're a CYP2D6 poor metabolizer at age 30 will use that information repeatedly across decades, including for pain medications after future surgery, beta blockers if they develop hypertension, and antidepressants if they ever need them.
Here are the specific phenotype outputs you'll see in a report from 23andMe data, with what each one means for drug response in practice.
Roughly 7 percent of people of European descent. Means standard doses of many antidepressants (paroxetine, venlafaxine, fluoxetine), ADHD medications (atomoxetine), and antipsychotics (aripiprazole, brexpiprazole) will produce higher plasma levels and more side effects than expected. For prodrugs like codeine and tramadol, it means the opposite: little to no pain relief because the drug can't activate properly.
Roughly 30 percent of people. Means SSRIs like sertraline, citalopram, and escitalopram clear faster than the label assumes, which can make standard doses sub-therapeutic. Also means PPIs like omeprazole may not reach therapeutic acid suppression at standard doses. Clopidogrel works fine in rapid metabolizers.
Roughly 2 to 5 percent of people of European descent, 15 to 20 percent of people of East Asian descent. Means standard-dose SSRIs accumulate to higher-than-expected plasma levels (often producing more side effects and QT prolongation risk at high citalopram doses), and clopidogrel fails to activate properly, leaving patients on Plavix with inadequate platelet protection.
Roughly 15 to 20 percent of people. Means simvastatin (especially at 80 mg) and high-dose atorvastatin carry elevated muscle pain risk. The fix is usually to switch within the statin class to pravastatin or rosuvastatin, not to stop statins entirely.
Your 23andMe data contains the genotype calls for all of these. Gene2Rx extracts them, maps them to CPIC and FDA phenotype categories, and produces the report. The underlying biology doesn't depend on which service interpreted the data; what differs is breadth of medication coverage and report format.
The highest-value moments to pull up your drug response report: before starting any new prescription medication, before a procedure where an opioid might be prescribed (codeine and tramadol are the main PGx-sensitive ones), when a medication you've tried hasn't worked as expected, or when a family member is starting treatment for a condition that runs in your family (your report applies to close relatives with useful probability).
Learn how genetics may affect your response to these related medications:
103 medications across every major drug class where CPIC or FDA has published pharmacogenetic guidance. That includes common antidepressants (sertraline, escitalopram, citalopram, paroxetine, venlafaxine, amitriptyline, vortioxetine), antipsychotics (aripiprazole, brexpiprazole, clozapine), ADHD medications (atomoxetine, amphetamine), pain medications (codeine, tramadol), cardiovascular drugs (clopidogrel, warfarin, metoprolol, statins), PPIs (omeprazole, pantoprazole), chemotherapy agents (capecitabine, fluorouracil, mercaptopurine, azathioprine, tamoxifen), immunosuppressants (tacrolimus), and infectious-disease drugs (abacavir, efavirenz, voriconazole).
Download the PDF from your Gene2Rx account and bring it to your next appointment, or email it to your clinician ahead of time. Highlight the medications relevant to your current discussion. Most pharmacogenetic-aware clinicians will take a few minutes to read the specific recommendations and factor them into their prescribing decision. If your doctor isn't familiar with pharmacogenetics, the specific CPIC and FDA source citations on each recommendation help them see the evidence base.
It can narrow the field meaningfully. If you're CYP2C19 poor metabolizer, citalopram and escitalopram are usually poor first choices because they accumulate and risk QT prolongation at higher doses. If you're CYP2D6 poor metabolizer, paroxetine and venlafaxine may hit plasma levels higher than expected. The report doesn't pick a specific antidepressant for you, but it rules out classes where your metabolizer phenotype makes standard dosing risky, which is often more than half the work.
Do not change anything on your own. Bring the specific findings to your prescribing clinician. For many patients, being a CYP2D6 or CYP2C19 poor metabolizer on a medication that's been working fine for years is informative but not urgent; you've demonstrated empirically that you tolerate the dose. For patients who have had side effects or inadequate response, the pharmacogenetic finding often explains the pattern and can guide a change to an alternative that works better.
Yes. 23andMe's own pharmacogenetic feature was pared back over time and now covers a limited number of variants with limited actionable recommendations. A full pharmacogenetic report from Gene2Rx covers 103 medications with per-phenotype recommendations from CPIC and FDA guidelines, which is substantially more than 23andMe's built-in feature provides.
For life. Your genetics don't change. The clinical guidelines the report is built on do occasionally update as new research emerges, so for high-stakes prescribing decisions it's worth re-running the report every few years to catch any material changes. For most use cases the report you generate today will still be accurate in 20 years.
Find out how your DNA may influence your response to Sertraline and other medications with a Gene2Rx pharmacogenetics report.
Get Your Report Try Our Free Calculator